» Authors » Colin Cunnington

Colin Cunnington

Explore the profile of Colin Cunnington including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 44
Citations 941
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Knops R, Lloyd M, Roberts P, Wright D, Boersma L, Doshi R, et al.
N Engl J Med . 2024 May; 391(15):1402-1412. PMID: 38767244
Background: The subcutaneous implantable cardioverter-defibrillator (ICD) is associated with fewer lead-related complications than a transvenous ICD; however, the subcutaneous ICD cannot provide bradycardia and antitachycardia pacing. Whether a modular pacing-defibrillator...
2.
Ahmed F, Sammut-Powell C, Martin G, Callan P, Cunnington C, Kahn M, et al.
ESC Heart Fail . 2024 May; 11(5):2637-2647. PMID: 38712903
Aims: Clinical pathways have been shown to improve outcomes in patients with heart failure (HF). Although patients with HF often have a cardiac implantable electronic device, few studies have reported...
3.
Soltani F, Lewis G, Rosala-Hallas A, Dodd S, Schelbert E, Williams S, et al.
J Card Fail . 2023 Mar; 29(7):1091-1096. PMID: 36921885
Objectives: Medication adherence in patients with heart failure with preserved ejection fraction is unclear. This study sought to evaluate treatment adherence in the Pirfenidone in Patients with Heart Failure and...
4.
Enab H, Cunnington C, Zaidi A
Heart Int . 2022 Oct; 15(2):103-105. PMID: 36277832
Lead displacement is a common complication of pacemaker device implantation, often resulting in prolonged hospital stays and increased costs. The frequency of long-term lead displacement ranges between 1.8% and 8.0%....
5.
Lewis G, Rosala-Hallas A, Dodd S, Schelbert E, Williams S, Cunnington C, et al.
J Am Heart Assoc . 2022 Jul; 11(14):e024668. PMID: 35861823
Background Growth differentiation factor 15 (GDF-15) is elevated in heart failure with preserved ejection fraction and is associated with adverse outcome, but its relationship with myocardial fibrosis and other characteristics...
6.
Lewis G, Rosala-Hallas A, Dodd S, Schelbert E, Williams S, Cunnington C, et al.
J Cardiovasc Transl Res . 2022 Jul; 15(6):1436-1443. PMID: 35790651
Myocardial fibrosis, measured using cardiovascular magnetic resonance extracellular volume (ECV), is associated with adverse outcome in heart failure with preserved ejection fraction, but the mechanisms by which myocardial fibrosis exerts...
7.
Lewis G, Rosala-Hallas A, Dodd S, Schelbert E, Williams S, Cunnington C, et al.
Int J Cardiovasc Imaging . 2022 Feb; 38(7):1569-1578. PMID: 35138474
Myocardial fibrosis, measured using magnetic resonance extracellular volume (ECV), associates with adverse outcome in heart failure with preserved ejection fraction (HFpEF). In the PIROUETTE (The Pirfenidone in Patients with Heart...
8.
Lewis G, Dodd S, Clayton D, Bedson E, Eccleson H, Schelbert E, et al.
Nat Med . 2021 Aug; 27(8):1477-1482. PMID: 34385704
In heart failure with preserved ejection fraction (HFpEF), the occurrence of myocardial fibrosis is associated with adverse outcome. Whether pirfenidone, an oral antifibrotic agent without hemodynamic effect, is efficacious and...
9.
Ahmed F, Taylor J, John A, Khan M, Zaidi A, Mamas M, et al.
ESC Heart Fail . 2021 Aug; 8(5):3906-3916. PMID: 34382749
Aims: This study aims to establish the feasibility, safety, and efficacy of outpatient intravenous (IV) diuretic treatment for the management of decompensated heart failure (HF) for patients enrolled in the...
10.
Guella E, Devereux F, Ahmed F, Scott P, Cunnington C, Zaidi A
Eur Heart J Case Rep . 2021 Aug; 5(7):ytab219. PMID: 34377899
Background: The use of transvenous pacing leads is associated with the risk of developing tricuspid valve (TV) dysfunction. This develops through several mechanisms including the failure of leaflet coaptation or...